Global pharmaceutical major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, in the United States. The product is bioequivalent to Eli Lilly’s Glucagon for Injection, 1mg/vial.
Glucagon is indicated for treating severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adults.
According to IQVIA MAT June 2025 data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit recorded estimated annual U.S. sales of USD 122 million.
Lupin, headquartered in Mumbai, operates in over 100 markets with a strong presence in India and the U.S. across multiple therapy areas. The company runs 15 manufacturing sites and seven research centers globally, supported by over 23,000 employees.
